Cannabis, vulnerability, and the onset of schizophrenia: An epidemiological perspective

References

• Rosenthal RN. Is schizophrenia addiction prone?. Current Opinion in Psychiatry 1998; 11: 45–48
   Web of Science ®Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Archives of General Psychiatry 1994; 51: 273–279
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Effect of substance misuse in early psychosis. British Journal of Psychiatry 1998; 172(Suppl. 33)34–136
   Google Scholar
• Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Australian and New Zealand Journal of Psychiatry 1995; 29: 69–74
   PubMed Web of Science ®Google Scholar
• Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. Journal of Nervous and Mental Disease 1987; 175: 641–652
   PubMed Web of Science ®Google Scholar
• Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 1991; 148: 224–230
   PubMed Web of Science ®Google Scholar
• Arndt S, Tyrrell G, Flaum M, Andreasen NC. Comorbidity of substance abuse and schizophrenia: the role of premorbid adjustment. Psychological Medicine 1992; 22: 379–388
   PubMed Web of Science ®Google Scholar
• Warner R, Taylor D, Wright J, et al. Substance use among the mentally ill: prevalence, reasons for use and effects on illness. American Journal of Orthopsychiatry 1994; 63: 30–39
   Google Scholar
• Soyka M, Albus M, Kathmann N, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. European Archives of Psychiatry and Clinical Neuroscience 1993; 242: 362–372
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin 1990; 16: 31–56
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatrica Scandinavica 1992; 85: 48–55
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Journal of the American Medical Association 1990; 264: 2511–2518
   PubMed Web of Science ®Google Scholar
• Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. Archives of General Psychiatry 1996; 53: 1022–1031
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th edn. American Psychiatric Association, Washington 1994
   Google Scholar
• Goldfinger SM, Schutt RK, Seidman LJ, Turner WM, Penk WE, Tolomiczenko GS. Self-report and observer measures of substance abuse among homeless mentally ill persons in the cross-section and over time. Journal of Nervous and Mental Disease 1996; 184: 667–672
   PubMed Web of Science ®Google Scholar
• Schwartz LS, Lyons JS, Stulp F, Hassan T, Jacobi N, Taylor J. Assessment of alcoholism among dually diagnosed psychiatric inpatients. Journal of Substance Abuse and Treatment 1993; 10: 255–261
   PubMed Web of Science ®Google Scholar
• Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 1993; 88: 21–24
   PubMed Web of Science ®Google Scholar
• Silver H, Abboud E. Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophrenia Research 1994; 13: 57–63
   PubMed Web of Science ®Google Scholar
• Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association?. British Journal of Psychiatry 1990; 157: 25–33
   PubMed Web of Science ®Google Scholar
• McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 1995; 15: 277–281
   PubMed Web of Science ®Google Scholar
• Test MA, Wallisch LS, Allness DJ, Ripp K. Substance abuse in young adults with schizophrenic disorders. Schizophrenia Bulletin 1989; 15: 465–476
   PubMed Web of Science ®Google Scholar
• Noordsy DL, Drake RE, Teague GB, et al. Subjective experiences related to alcohol use among schizophrenics. Journal of Nervous and Mental Disease 1991; 179: 410–414
   PubMed Web of Science ®Google Scholar
• Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996; 40: 1155–1163
   PubMed Web of Science ®Google Scholar
• Docherty JP, van Kammen DP, Siris SG, Marder SR. Stages of onset of schizophrenic psychosis. American Journal of Psychiatry 1978; 135: 420–426
   PubMed Web of Science ®Google Scholar
• Häfner H, Riecher-Rössler A, Maurer K, Fätkenheuer B, Löffler W. First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. European Archives of Psychiatry and Clinical Neuroscience 1992; 242: 109–118
   PubMed Web of Science ®Google Scholar
• Häfner H, Maurer K, Löffler W, Riecher-Rössler A. The influence of age and sex on the onset and early course of schizophrenia. British Journal of Psychiatry 1993; 162: 80–86
   PubMed Web of Science ®Google Scholar
• Häfner H, Riecher-Rössler A, Hambrecht M, et al. IRAOS: an instrument for the retrospective assessment of the onset of schizophrenia. Schizophrenia Research 1992; 6: 209–223
   PubMed Web of Science ®Google Scholar
• Wing JK, Cooper JE, Sartorius N. Measurement and classification of psychiatric symptoms. Cambridge University Press, Cambridge 1974
   Google Scholar
• Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1982; 39: 784–788
   PubMed Web of Science ®Google Scholar
• World Health Organization. Psychiatric disability assessment schedule (WHO/DAS). WHO, Geneva 1988
   Google Scholar
• Hambrecht M, Häfner H, Löffler W. Beginning schizophrenia observed by significant others. Social Psychiatry and Psychiatric Epidemiology 1994; 29: 53–60
   PubMed Web of Science ®Google Scholar
• Zubin J, Spring B. Vulnerability: a new view of schizophrenia. Journal of Abnormal Psychology 1977; 86: 103–126
   PubMed Web of Science ®Google Scholar
• Nuechterlein K. Vulnerability models for schizophrenia: state of the art. Search for the causes of schizophrenia, H Häfner, W Janzarik. Springer, Berlin 1987; 297–316
   Google Scholar
• Castle DJ, Ames FR. Cannabis and the brain. Australian and New Zealand Journal of Psychiatry 1996; 30: 179–183
   PubMed Web of Science ®Google Scholar
• Lundquist T. Cognitive dysfunctions in chronic cannabis users. Almquist and Wiksell International, Stockholm 1995
   Google Scholar
• Gardner EL, Lowinson JH. Marijuana's interaction with brain reward systems: update 1991. Pharmacology and Biochemistry of Behavior 1991; 40: 571–580
   PubMed Web of Science ®Google Scholar
• Bundesminister für Gesundheit. Daten des Gesundheitswesens Ausgabe 1991. Schriftenreihe des Bundesministeriums für Gesundheit. Nomos, Baden-BadenGermany 1991; Bd. 3
   Google Scholar